|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multi-marker analysis revealed a significant contribution of IgG3 responses to malaria protection and IgG2 responses to malaria risk.
|
30930896 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgG3, known to have the shortest half-life of the IgG subclasses, might be the most temporally relevant indicator of ongoing malaria exposure when examining antibody responses to AMA1.
|
30658710 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
However infants from CAIG (n = 53) had significantly higher AMA1-, MSP2-FC27-, MSP3-specific IgG1 and AMA1-, MSP1-, MSP2-FC27-, MSP3 and GLURP-R2-specific IgG3 than those from NCIG (n = 183).
|
31185998 |
2019 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, a combination of IgG3 antibody responses against Pf12, MSP3.7, MSP3.3, and MSP2FC27 was strongly associated with protection against febrile malaria (HR = 0.15; 95% CI, .06-.37; P = .0001).
|
29733355 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support previous studies that found OP of merozoites to be associated with protection against malaria and further shows IgG3 and GLURP antibodies are key in the OP mechanism, thus giving further impetus for the development of malaria vaccines targeting GLURP.
|
28329101 |
2017 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examines the hypotheses that the IgG3-H435 variant promotes increased transplacental transfer of malaria-specific antibodies and a prolonged IgG3 half-life in infants and that its presence correlates with protection against clinical malaria during infancy.
|
28991911 |
2017 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because high anti-parasite IgG3 and low anti-parasite IgG4 levels were associated with malaria resistance, the chromosomal regions linked to IgG3 and IgG4 levels are of special interest.
|
25521226 |
2016 |
|
Malaria
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a family-based association study encompassing 483 Sereer individuals (261 children and their parents), and reported two independent signals at the HLA-G 3' untranslated region associated with antibody response to specific Plasmodium falciparum blood stage antigens, previously associated with malaria protection: (i) +3010G together with +3142C with total IgG and IgG1 against GLURP and (ii) +3196G with IgG3 against MSP2.
|
23745572 |
2013 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, our main objective was to study the changes in MSP2-specific total IgG, IgG1 and IgG3 responses during a malaria transmission season in order to assess the impact of sickle-cell, α(+)-thalassemia and G6PD variants on antibody kinetics.
|
21549219 |
2011 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we reported that the levels of IgG2 and IgG3 to Pf332-C231 malaria antigen are negatively correlated with number of malaria episodes.
|
21729768 |
2011 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IL4-590T allele was significantly associated with anti-P. falciparum IgG3 antibody levels in patients with complicated (P = 0.031), but not with uncomplicated malaria (P = 0.622).
|
20003246 |
2009 |
|
Malaria
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The highest levels of IgG, IgG1, IgG2 and IgG3 antibodies were observed in individuals with asymptomatic and uncomplicated malaria, while highest levels of IgG4, IgE and IgM antibodies were predominant among individuals with complicated malaria.
|
18816374 |
2008 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 30 immune responses measured, only one, antibodies of the IgG3 isotype directed to merozoite surface protein 3 (MSP3), was strongly associated with clinical protection against malaria in all age groups, i.e., independently of age.
|
18001147 |
2007 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of IgG and IgG3 to MSP2/3D7 were negatively associated with the risk of occurrence of a malaria attack during the following transmission season.
|
16679042 |
2006 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.
|
14507328 |
2003 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
(3) The overall pattern of human IgG antibody responses to MSP-2 in Karitiana Indians, a population continuously exposed to hypoendemic malaria in the Brazilian Amazon Region, differs from that described in hyperendemic areas in Africa and Papua New Guinea in two important features: there was no clear age-dependent increase in the prevalence and mean concentration of specific IgG antibodies, and there was no skewing towards the IgG3 subclass in antibody responses.
|
11596920 |
2002 |
|
Malaria
|
0.100 |
Biomarker
|
disease |
BEFREE |
(i) All blocks were targeted by naturally acquired cytophilic antibodies of the subclasses IgG1 and IgG3, but the balance between IgG1 and IgG3 depended on the subjects' cumulative exposure to malaria.
|
10531247 |
1999 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We previously developed a mouse/human chimeric IgG3 targeting human TfR1 (ch128.1), which exhibits significant antitumor activity against multiple myeloma (MM) in xenograft models of SCID-Beige mice bearing disseminated ARH-77 or KMS-11 tumors.
|
31693515 |
2020 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In conclusion, human IgG3 does not have improved therapeutic efficacy compared to human IgG1 in a mouse tumour model.
|
28542406 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that anti-HER2/neu IgG3-(IL-2), (IL-12)-IgG3, or IgG3-(GM-CSF) antibody fusion proteins (mono-AbFPs) elicit anti-tumor activity against murine tumors expressing HER2/neu when used as adjuvants of extracellular domain of HER2/neu (ECD(HER2)) protein vaccination.
|
16125282 |
2006 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Anti-HER2 IgG3-endostatin inhibited tumor growth significantly more effectively than endostatin, anti-HER2 IgG3 antibody, or the combination of antibody and endostatin.
|
15956253 |
2005 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Genes most abundantly expressed in the invasive tumor were immunoglobulin heavy constant gamma 3 and calgranulin B.
|
12894577 |
2003 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Production of IgG3 appears common, but IgG1, IgG2, IgA1, and IgA2 also arise, indicating a continuing influence of a directed process on the tumor clone.
|
11493467 |
2001 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The isotype of the antibody response to HER2/neu is consistent with a switch from a Th2 to a Th1 immune response and the infiltration of mononuclear cell in tumors from mice treated with mscIL-12.her2.IgG3.
|
11576465 |
2001 |